Advances in CGRP Monoclonal Antibodies as Migraine Therapy: A Narrative Review.

Aditya, Suruchi et al.·Saudi journal of medicine & medical sciences·2023·
RPEP-066682023RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

CGRP mAbs decrease headache days and improve disability in migraine patients.

Key Numbers

How They Did This

The article is a narrative review summarizing recent advances in CGRP monoclonal antibody therapy for migraines.

Why This Research Matters

CGRP mAbs represent a significant advancement in migraine treatment, addressing the need for more effective and safer options. This could lead to better management of a condition that affects many individuals.

What This Study Doesn't Tell Us

The review does not provide new experimental data and relies on existing studies, which may vary in quality and scope.

Trust & Context

Original Title:
Advances in CGRP Monoclonal Antibodies as Migraine Therapy: A Narrative Review.
Published In:
Saudi journal of medicine & medical sciences, 11(1), 11-18 (2023)
Database ID:
RPEP-06668

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-06668·https://rethinkpeptides.com/research/RPEP-06668

APA

Aditya, Suruchi; Rattan, Aditya. (2023). Advances in CGRP Monoclonal Antibodies as Migraine Therapy: A Narrative Review.. Saudi journal of medicine & medical sciences, 11(1), 11-18. https://doi.org/10.4103/sjmms.sjmms_95_22

MLA

Aditya, Suruchi, et al. "Advances in CGRP Monoclonal Antibodies as Migraine Therapy: A Narrative Review.." Saudi journal of medicine & medical sciences, 2023. https://doi.org/10.4103/sjmms.sjmms_95_22

RethinkPeptides

RethinkPeptides Research Database. "Advances in CGRP Monoclonal Antibodies as Migraine Therapy: ..." RPEP-06668. Retrieved from https://rethinkpeptides.com/research/aditya-2023-advances-in-cgrp-monoclonal

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.